Medivir Aktiebolag financials

Medivir Aktiebolag

Country: SE Reporting currency: SEK Latest annual report: 2024-12-31
LEI: 549300VWDGUX0WMJ1T79
Source filing ↗
Financial statements (SEK, as reported — unscaled; 76 line items across 2 annual periods)
Line item 20242023
Income statement
Employee benefits expense SEK 27.2MSEK 27.4M
Depreciation & amortisation SEK 2.7MSEK 2.7M
Operating profit (EBIT) -SEK 127.3M-SEK 91.4M
Finance costs SEK 783.0KSEK 913.0K
Profit before tax -SEK 123.3M-SEK 89.3M
Profit for the year -SEK 123.3M-SEK 89.3M
— attributable to owners -SEK 123.3M-SEK 89.3M
Total comprehensive income -SEK 123.3M-SEK 89.4M
Per share
Basic EPS SEK -1.08SEK -1.48
Diluted EPS SEK -1.08SEK -1.48
Free cash flow / share SEK -1.09SEK -0.99
Cash flow statement
Cash generated from operations -SEK 119.3M-SEK 86.1M
Net cash from operating activities -SEK 124.2M-SEK 59.7M
Net cash from investing activities SEK 0-SEK 261.0K
Purchase of PP&E (capex) SEK 0SEK 0
Net cash from financing activities SEK 17.2MSEK 112.1M
Lease liability payments SEK 2.5MSEK 2.0M
Net change in cash -SEK 107.0MSEK 52.1M
Balance sheet
Total assets SEK 172.6MSEK 287.9M
Non-current assets SEK 105.9MSEK 108.7M
Property, plant & equipment SEK 9.6MSEK 12.4M
Right-of-use assets SEK 9.6MSEK 12.2M
Current assets SEK 66.6MSEK 179.2M
Trade & other receivables SEK 4.1MSEK 9.7M
Cash & equivalents SEK 62.5MSEK 169.5M
Total equity SEK 115.5MSEK 217.9M
Non-current liabilities SEK 8.6MSEK 11.3M
Lease liabilities (non-current) SEK 8.6MSEK 11.3M
Current liabilities SEK 48.5MSEK 58.7M
Lease liabilities (current) SEK 2.5MSEK 2.3M
Derived metrics
Free cash flow -SEK 124.2M-SEK 59.7M
Return on equity -106.8%-41.0%
Cash conversion ratio 1.01×0.67×
Other reported items
Additional Paidin Capital SEK 926.0MSEK 910.3M
Adjusted Weighted Average Shares 114.1M60.4M
Adjustments For Decrease Increase In Trade and Other Receivables SEK 5.6M-SEK 4.1M
Adjustments For Increase Decrease In Trade and Other Payables -SEK 10.4MSEK 30.6M
Cash SEK 10.8MSEK 25.6M
Cash Equivalents SEK 51.7MSEK 144.0M
Cash Flows From Used In Operations Before Changes In Working Capital -SEK 119.3M-SEK 86.1M
Current Accrued Expenses and Other Current Liabilities SEK 32.5MSEK 38.8M
Current Prepayments and Current Accrued Income Including Current Contract Assets SEK 1.8MSEK 6.9M
Current Tax Assets Current SEK 1.4MSEK 1.4M
Effect of Exchange Rate Changes On Cash and Cash Equivalents SEK 0-SEK 64.0K
Equity and Liabilities SEK 172.6MSEK 287.9M
Finance Income SEK 4.8MSEK 3.0M
Gains Losses On Exchange Differences On Translation Net of Tax SEK 0-SEK 64.0K
Increase Decrease Through Exercise of Warrants Equity SEK 1.6MSEK 1.2M
Intangible Assets Other Than Goodwill SEK 96.3MSEK 96.3M
Intangible Assets Under Development SEK 96.3MSEK 96.3M
Issue of Equity SEK 20.0MSEK 129.0M
Issued Capital SEK 57.3MSEK 52.7M
Miscellaneous Other Operating Expense SEK 639.0KSEK 1.4M
Noncurrent Financial Assets SEK 0SEK 0
Number of Shares Outstanding 114.6M105.4M
Other Adjustments For Noncash Items SEK 4.0MSEK 3.2M
Other Comprehensive Income SEK 0-SEK 64.0K
Other Current Payables SEK 1.4MSEK 1.3M
Other Current Receivables SEK 889.0KSEK 1.3M
Other Expense By Nature SEK 101.3MSEK 68.9M
Other Intangible Assets SEK 0SEK 0
Other Noncurrent Financial Assets SEK 0SEK 0
Other Operating Income Expense SEK 978.0KSEK 1.4M
Other Property Plant and Equipment SEK 85.0KSEK 212.0K
Par Value Per Share SEK 0.50SEK 0.50
Payments For Share Issue Costs SEK 700.0KSEK 15.7M
Proceeds From Issuing Other Equity Instruments SEK 0SEK 0
Proceeds From Issuing Shares SEK 20.4MSEK 129.7M
Purchase of Other Longterm Assets Classified As Investing Activities SEK 0SEK 261.0K
Reserve of Exchange Differences On Translation -SEK 3.3M-SEK 3.3M
Retained Earnings -SEK 864.5M-SEK 741.7M
Revenue and Operating Income SEK 4.5MSEK 9.0M
Revenue From Royalties SEK 3.5MSEK 7.6M
Share Issue Related Cost SEK 700.0KSEK 15.7M
Trade and Other Current Payables To Trade Suppliers SEK 12.1MSEK 16.4M
Weighted Average Shares 114.1M60.4M
Methodology

Every line item above is a fact tagged in Medivir Aktiebolag's annual report filed in the European Single Electronic Format (ESEF) under the IFRS taxonomy (ifrs-full) — the income statement, balance sheet and cash-flow statement as the filer reported them. Values are shown as-is, in the reporting currency (SEK), without rescaling; the row labels map to the underlying concept name (e.g. Revenue → ifrs-full:Revenue, Operating profit → ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS → ifrs-full:DilutedEarningsLossPerShare), and any concept without a curated label is shown under “Other reported items” with its de-camel-cased tag name. Only consolidated, default-member facts are shown (segment / dimensional breakdowns are excluded).

“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.

Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.